CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies.
Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
没有特定的超声心动图变量可预测 CRS 2 的发生,因此导致血流动力学失代偿并引起低氧血症和低血压加重的机制可能是多因素的,且并非直接由心脏介导。
CD19 CAR-T 细胞疗法是一种新型抗癌治疗,在复发/难治性B细胞血液系统恶性肿瘤中已产生显著疗效。细胞因子释放综合征(CRS)是CAR-T 细胞输注后常见的免疫失调反应,可导致心功能障碍和循环衰竭,对疗效和生存产生不利影响。为应对CRS造成的损害,患者通常在治疗前接受筛查,以确认心脏储备功能足够。基线超声心动图评估的心功能与中重度CRS的发生之间是否相关,目前尚不明确。
本研究旨在确定可预测血流动力学显著CRS(CRS≥2级)的基线超声心动图变量,评估其随访变化,并考察癌症治疗相关心功能障碍(CTRCD)的发生率。研究纳入接受CD19 CAR-T 细胞疗法且有基线超声心动图的患者,开展观察性回顾性队列研究。从电子病历中提取人口学、临床和超声心动图变量。按是否发生CRS<2级或≥2级对患者分组并进行比较。采用校正后的逻辑回归分析评估超声心动图变量与CRS≥2级发生之间的关联。
研究共纳入291名患者,中位年龄60岁(四分位距:51–67岁),73%为男性,71%患弥漫性大B细胞淋巴瘤。逻辑回归分析未发现任何基线超声心动图指标可显著预测CRS≥2级,包括左心室射血分数和整体纵向应变。总体而言,以及在两个CRS分组中,随访时收缩和舒张期超声心动图指标均保持在正常范围。CTRCD发生率为4.5%,且多数发生于CRS≥2级患者中。
没有特定超声心动图指标能够预测CRS≥2级的发生。因此,导致血流动力学失代偿并引起低氧和低血压加重的机制可能是多因素的,且未必由心脏直接介导。
CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively impacting outcomes and survival. To endure the insults of CRS, patients are typically screened for adequate cardiac reserve before treatment. The relationship between baseline cardiac function by echocardiography and the development of moderate to severe presentations of CRS is unclear.
This study aimed to identify baseline echocardiographic variables that can predict the development of hemodynamically significant CRS (CRS 2), evaluate their behavior at follow-up, and investigate the incidence of cancer therapy-related cardiac dysfunction (CTRCD). An observational retrospective cohort study of patients treated with CD19 CAR T-cell therapy with a baseline echocardiogram was performed. Demographic, clinical and echocardiographic variables were abstracted from the electronic health record. Patients were grouped and compared by the occurrence of CRS < 2 and 2. Adjusted logistic regression analysis was used to evaluate the association between echocardiographic variables and the development of CRS 2.
291 patients were included in the study. Median age was 60 (IQR: 51, 67 years), 73% were male, and 71% had diffuse large B-cell lymphoma. Logistic regression analysis did not reveal any significant baseline echocardiographic predictors of CRS 2, including left ventricular ejection fraction and global longitudinal strain. Systolic and diastolic echocardiographic variables remained within normal limits at follow-up overall and in both CRS groups. The incidence of CTRCD was 4.5% and occurred mostly in the setting of CRS 2.
No specific echocardiographic variables predicted the development of CRS 2, and therefore the mechanism leading to hemodynamic decompensation and producing worsening hypoxia and hypotension could be multifactorial and not directly cardiac mediated.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。